Eomesodermin-expressing CD4+ Th cells and association with pregnancy in multiple sclerosis.

Background

Pregnancy in patients with multiple sclerosis (MS) is accompanied by a decline of relapse activity with increased risk of relapses 3 months post-partum, for unknown reasons. Eomesodermin

Objectives

Here, investigated immune cell alterations and the pathophysiological role of Eomes

Methods

We enrolled

Results

While CD3

Discussion

Pregnancy in MS is associated with robust immunological alterations. Eomes

Informations de copyright

© The Author(s), 2024.

Déclaration de conflit d'intérêts

SF has received speaker’s and/or scientific board honoraria from AstraZeneca, Biogen, BMS, Celgene, Janssen, Merck, Novartis and Roche; and grant support from Ruhr-University Bochum, DMSG, Stiftung für therapeutische Forschung, Lead Discovery Center GmbH and Novartis. MB and PT have received funding from the FoRUM-program of the Medical Faculty of Ruhr-University Bochum. ST has nothing to disclose. TY has received speaker honoraria from Biogen, Novartis, Chugai, Takeda, Mitsubishi-Tanabe, Miyarisan and Sumitomo Pharma; serves on the editorial boards of Therapeutic Advances in Neurological Diseases and Clinical and Experimental Neuroimmunology; receives research support from Novartis and Chiome Bioscience; and receives royalties from EA Pharma. KH has received travel grants from Biogen, Novartis and Merck; and received speaker and research honoraria from Biogen Idec Germany, Teva, Sanofi Genzyme, Novartis, Bayer Health-Care, Merck Serono and Roche. RG serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen, Bayer Schering Pharma and Novartis; has received speaker honoraria from Biogen, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono and Novartis. Because RG is Editor-in-Chief of this journal, the peer review process was managed by alternative members of the Board and the submitting Editor was not involved in the decision-making process.